Related Experiment Videos
[Phenacetin, paracetamol and bladder cancer].
1Kraeftens Bekaempelse, København, Cancerregisteret, institut for cancerepidemiologi.
Ugeskrift for Laeger
|December 3, 1990
Summary
Phenacetin-containing analgesics are linked to increased cancer risk, particularly in the renal pelvis. Phenacetin was withdrawn from Denmark in 1985 due to these concerns.
Area of Science:
- Toxicology
- Oncology
- Pharmacology
Context:
- Widespread analgesic use in Denmark.
- Concerns regarding phenacetin and cancer risk.
- Phenacetin withdrawal from the Danish market in 1985.
Purpose:
- To review the evidence linking phenacetin-containing analgesics to cancer.
- To assess the carcinogenic potential of phenacetin and paracetamol.
- To inform public health regarding analgesic safety.
Summary:
- Combination analgesics containing phenacetin are associated with an increased risk of renal pelvis tumors.
- Limited evidence suggests phenacetin may also increase bladder cancer risk.
- The carcinogenic effect of paracetamol (acetaminophen) in humans is sparsely documented, with no reported increased risk for bladder cancer.
Impact:
- Phenacetin withdrawal in Denmark highlights the importance of drug safety monitoring.
- Increased paracetamol use may warrant further investigation into its long-term effects.
- Understanding analgesic carcinogenicity is crucial for public health and regulatory decisions.